세계의 요오드화나트륨(131I) 시장 : 유형, 제품 형태, 제조 방법, 용도, 최종 이용 산업별 - 예측(2025-2030년)

The Sodium Iodide [131I] Market was valued at USD 736.80 million in 2024 and is projected to grow to USD 779.02 million in 2025, with a CAGR of 5.94%, reaching USD 1,041.82 million by 2030.

Sodium Iodide [131I] plays a pivotal role in modern nuclear medicine and industrial applications, marking a turning point in both therapeutic and diagnostic arenas. As the demand for precision interventions grows, this radioactive isotope has become an essential component in radiopharmaceutical formulations and various research initiatives. Recent advancements in technology and regulatory measures have bolstered the reliability of production methods, ensuring that both quality and safety meet the highest international standards.

In today's dynamic environment, stakeholders are witnessing a transformation that blends traditional methodologies with innovative production techniques. The evolution of Sodium Iodide [131I] is reflective of a broader trend within the industry-a shift toward more efficient, safe, and cost-effective practices that support clinical excellence and industrial reliability. In this comprehensive analysis, we explore the multifaceted roles of Sodium Iodide [131I] in diagnostic imaging, radiotherapeutic procedures, and scientific research. Each development underlines the importance of technological integration and regulatory advancements in maintaining the momentum of industry growth.

Moreover, insights into evolving market dynamics suggest that an integrated approach-combining rigorous quality control with progressive research-can dramatically enhance both the production and application of Sodium Iodide [131I]. This introductory overview provides the necessary context for understanding subsequent analyses on market segmentation, regional trends, and strategic company initiatives.

Transformative Shifts in Production, Application, and Market Dynamics

Over the past few years, the market for Sodium Iodide [131I] has experienced transformative shifts that are reshaping its landscape, both in production and application. Companies and institutions have been quick to adopt advanced technologies which enhance the reliability and efficiency of production methods. Innovations in accelerator-based and reactor-based techniques have significantly reduced production times while ensuring that quality and safety remain uncompromised.

The transformation is also evident in the shift towards personalized medicine, where accurate diagnostic imaging and targeted therapy are critical. This evolution has spurred investments in state-of-the-art linear accelerators and hadron accelerators that play a central role in the production process. Concurrently, traditional reactor-based production is undergoing reformation with cyclotron irradiation and uranium fission reactors adapting to newer standards of efficiency and safety.

These shifts are propelled by regulatory frameworks and a growing body of research that continually validates and refines operational protocols. The market is steadily transitioning from conventional practices towards integrated, high-tech solutions that meet both clinical and industrial demands. Today's landscape reflects an era of dynamic change, where collaborative strategies and technological advancements are driving both innovation and competitive advantage in the rapidly evolving field of nuclear medicine and research.

Segmentation Insights across Production, Form, Application, and End-use Industries

Detailed segmentation analysis of the Sodium Iodide [131I] market reveals a complex structure that caters to multiple facets of production, form, application, and end-user industries. First, when looking at the type, the market is distinguished by two primary categories: Pure Sodium Iodide [131I] and Radiopharmaceuticals. This classification underscores the dual nature of the product, serving as both a standalone element and an integral component in diverse therapeutic procedures.

The product is available in various forms including capsule, liquid, and solid, each offering its own set of benefits related to ease of administration, stability, and dosage accuracy. The form of the product is critical in ensuring that it meets the specific requirements of different clinical and research settings. In addition, the production method is another vital segmentation parameter. The industry capitalizes on both accelerator-based production and reactor-based production. Accelerator-based approaches are further refined by applications involving hadron accelerators and linear accelerators, whereas reactor-based production leverages cyclotron irradiation and uranium fission reactors. These innovative methodologies ensure that production is both scalable and adaptable to evolving regulatory standards.

Beyond production techniques, the market finds further segmentation based on application. The industrial segment addresses niche use-cases such as radiation shielding and radiotracer applications. Meanwhile, the medical sector is a primary consumer, particularly in diagnostic imaging, radiopharmaceutical production, and therapeutic procedures. Additionally, research applications in chemical synthesis and nuclear medicine research continue to drive market expansion. Finally, segmentation by end-use industry highlights the broad scope of these products-from academic and research institutions, chemical and biotechnology industries, to healthcare and pharmaceutical sectors, and even nuclear energy plants, thereby reflecting the extensive market reach and diverse application landscape of Sodium Iodide [131I].

Based on Type, market is studied across Pure Sodium Iodide [131I] and Radiopharmaceuticals.

Based on Form, market is studied across Capsule Form, Liquid Form, and Solid Form.

Based on Production Method, market is studied across Accelerator-Based Production and Reactor-Based Production. The Accelerator-Based Production is further studied across Hadron Accelerators and Linear Accelerators. The Reactor-Based Production is further studied across Cyclotron Irradiation and Uranium Fission Reactors.

Based on Application, market is studied across Industrial, Medical, and Research. The Industrial is further studied across Radiation Shielding and Radiotracer Applications. The Medical is further studied across Diagnostic Imaging, Radiopharmaceutical Production, and Therapeutic Procedures. The Research is further studied across Chemical Synthesis and Nuclear Medicine Research.

Based on End-Use Industry, market is studied across Academic & Research Institutions, Chemical & Biotechnology Industries, Healthcare & Pharmaceuticals, and Nuclear Energy Plants.

Regional Market Trends and Emerging Opportunities

The global landscape of the Sodium Iodide [131I] market is characterized by distinctive regional trends shaped by varying economic, regulatory, and technological factors. In the Americas, the market tends to be driven by robust healthcare infrastructure and significant investments in nuclear medicine. This is complemented by a mature industrial base that ensures steady demand for innovative radiopharmaceuticals.

In the Europe, Middle East & Africa region, regulatory frameworks and strategic partnerships play a definitive role in steering market growth. Here, rigorous quality standards and a commitment to technological advancement enhance the production efficiency and broaden the scope of applications. Meanwhile, the Asia-Pacific region is emerging as a key growth nexus, fueled by rapid industrialization, increasing healthcare expenditure, and collaborative research initiatives. The dynamism in this region is largely attributed to progressive regulatory amendments and heightened awareness regarding advanced diagnostic and therapeutic protocols.

Collectively, these regional insights highlight a diverse yet interlinked global market where localized trends coalesce to create a competitive environment. The evolving regulatory landscape, varying degrees of technological adoption, and growing consumer awareness are converging to promote sustainable growth in each region.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Industry Players Driving Market Innovation

Several key companies are instrumental in driving innovation and pushing the boundaries in the Sodium Iodide [131I] market. Industry leaders such as Cardinal Health, Inc. and China Isotope & Radiation Corporation are recognized for their pioneering production techniques and broad market reach. Firms like Curium Pharma and Eckert & Ziegler Radiopharma GmbH continue to innovate in radiopharmaceutical development, ensuring that advanced medical imaging and therapeutic procedures remain within reach for a global patient base.

Other influential players, including GE Healthcare, Inc. and the Institute of Isotopes Co., Ltd., have established themselves by consistently adhering to high industry standards and leveraging advanced technological infrastructures. The contributions of International Isotopes Inc. and Isotope JSC further illustrate the sector's commitment to quality and innovation. Moreover, companies such as Jubilant DraxImage Inc. and Mallinckrodt Pharmaceuticals have broadened the spectrum of applications by integrating cutting-edge research into their product lines.

Additional market influencers like MEDSNAB LLC, Nordion Inc., NorthStar Medical Technologies, LLC, and NTP Radioisotopes SOC Ltd have expanded offerings in both medical and industrial segments. Key collaborations and strategic investments by PDRadiopharma Inc., Shandong Xinhua Pharma, Siemens Healthineers AG, Telix Pharmaceuticals Limited, and Yantai Dongcheng Pharmaceutical Group Co. Ltd. further consolidate the sector's robust network of expertise, thereby driving the overall momentum and fostering a competitive environment in the global market.

The report delves into recent significant developments in the Sodium Iodide [131I] Market, highlighting leading vendors and their innovative profiles. These include Cardinal Health, Inc., China Isotope & Radiation Corporation, Curium Pharma, Eckert & Ziegler Radiopharma GmbH, GE Healthcare, Inc., Institute of Isotopes Co., Ltd., International Isotopes Inc., Isotope JSC, Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals, MEDSNAB LLC, Nordion Inc., NorthStar Medical Technologies, LLC, NTP Radioisotopes SOC Ltd, PDRadiopharma Inc., Shandong Xinhua Pharma, Siemens Healthineers AG, Telix Pharmaceuticals Limited, and Yantai Dongcheng Pharmaceutical Group Co. Ltd.. Actionable Recommendations for Strategy and Growth

Industry leaders can unlock significant growth opportunities by implementing actionable strategies that navigate the intricacies of the Sodium Iodide [131I] market. To maintain competitive advantage, companies should consider investing in advanced production technologies that ensure high quality and efficient output, particularly by embracing both accelerator-based and reactor-based methods. These investments will help in optimizing production workflows while reducing operational risks and costs.

In addition, integrating cross-functional collaborations between research institutions, healthcare providers, and industrial partners can foster groundbreaking innovation. Leaders are encouraged to leverage data-driven insights and market segmentation intelligence to tailor products for diverse applications-ranging from diagnostic imaging to industrial radiotracer applications. This multidimensional approach not only enhances product versatility but also addresses the specific needs of different end-user industries including academic, chemical, and pharmaceutical sectors.

Furthermore, capitalizing on emerging regional opportunities is paramount. An agile strategy that adapts to regional regulatory frameworks, consumer preferences, and technology adoption trends can drive market penetration. Companies should also prioritize investments in research and development, focusing on enhancing product efficacy and safety. By cultivating a culture of continuous improvement and innovation, industry leaders can enhance their market positioning, counter competitive pressures, and pave the way for sustainable growth.

Final Thoughts on Market Dynamics and Future Outlook

In summary, the evolution of the Sodium Iodide [131I] market is being driven by technological innovations, evolving regulatory mandates, and comprehensive segmentation strategies that cater to diverse applications. The integration of advanced production methodologies with customized solutions has positioned this market at the forefront of both industrial and medical advancements. Stakeholders now have a clearer roadmap for navigating an increasingly competitive landscape, where adaptability and strategic investments are key.

The concerted efforts by major industry players and regional markets are shaping a future where efficiency, quality, and innovation coalesce to form a robust market framework. This holistic overview not only highlights the current industry dynamics but also sets the stage for future advancements that promise to redefine therapeutic and diagnostic paradigms.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Expanding use of sodium iodide [131I] for personalized treatment approaches in oncology, fueling market growth
    • 5.1.1.2. Growing advancements in nuclear medicine and radiopharmaceutical technologies boosting the adoption of sodium iodide [131I] in diagnostics and treatment
    • 5.1.1.3. Increasing need for targeted cancer therapies using sodium iodide [131I] for radioiodine therapy in thyroid cancer treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Regulatory challenges and strict safety protocols for the manufacturing and handling of sodium iodide [131I] limiting market growth
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing research and development investments in sodium iodide [131I] to enhance its therapeutic applications and improve patient outcomes
    • 5.1.3.2. Emergence of novel radioactive iodine-based therapies for rare cancers, providing new growth avenues for sodium iodide [131I] market players
  • 5.1.4. Challenges
    • 5.1.4.1. Potential side effects such as thyroid dysfunction and radiation exposure risks associated with sodium iodide [131I] therapy, affecting patient acceptance
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Role of sodium iodide [131I] in radiopharmaceuticals for cancer treatment and diagnostics
  • 5.2.2. End-Use Industry: Significance of sodium iodide [131I] in chemical & biotechnology industries for drug development and molecular imaging
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Sodium Iodide [131I] Market, by Type

• 6.1. Introduction
• 6.2. Pure Sodium Iodide [131I]
• 6.3. Radiopharmaceuticals

7. Sodium Iodide [131I] Market, by Form

• 7.1. Introduction
• 7.2. Capsule Form
• 7.3. Liquid Form
• 7.4. Solid Form

8. Sodium Iodide [131I] Market, by Production Method

• 8.1. Introduction
• 8.2. Accelerator-Based Production
  • 8.2.1. Hadron Accelerators
  • 8.2.2. Linear Accelerators
• 8.3. Reactor-Based Production
  • 8.3.1. Cyclotron Irradiation
  • 8.3.2. Uranium Fission Reactors

9. Sodium Iodide [131I] Market, by Application

• 9.1. Introduction
• 9.2. Industrial
  • 9.2.1. Radiation Shielding
  • 9.2.2. Radiotracer Applications
• 9.3. Medical
  • 9.3.1. Diagnostic Imaging
  • 9.3.2. Radiopharmaceutical Production
  • 9.3.3. Therapeutic Procedures
• 9.4. Research
  • 9.4.1. Chemical Synthesis
  • 9.4.2. Nuclear Medicine Research

10. Sodium Iodide [131I] Market, by End-Use Industry

• 10.1. Introduction
• 10.2. Academic & Research Institutions
• 10.3. Chemical & Biotechnology Industries
• 10.4. Healthcare & Pharmaceuticals
• 10.5. Nuclear Energy Plants

11. Americas Sodium Iodide [131I] Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Sodium Iodide [131I] Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Sodium Iodide [131I] Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Sanofi ventures into radiopharmaceuticals with EUR 100 million deal for AlphaMedix
  • 14.3.2. Study by Boston University reveals surgical and radioactive iodine treatments significantly lower cardiovascular risks in hyperthyroid patients
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Cardinal Health, Inc.
• 2. China Isotope & Radiation Corporation
• 3. Curium Pharma
• 4. Eckert & Ziegler Radiopharma GmbH
• 5. GE Healthcare, Inc.
• 6. Institute of Isotopes Co., Ltd.
• 7. International Isotopes Inc.
• 8. Isotope JSC
• 9. Jubilant DraxImage Inc.
• 10. Mallinckrodt Pharmaceuticals
• 11. MEDSNAB LLC
• 12. Nordion Inc.
• 13. NorthStar Medical Technologies, LLC
• 14. NTP Radioisotopes SOC Ltd
• 15. PDRadiopharma Inc.
• 16. Shandong Xinhua Pharma
• 17. Siemens Healthineers AG
• 18. Telix Pharmaceuticals Limited
• 19. Yantai Dongcheng Pharmaceutical Group Co. Ltd.